ArticleChinese journal of cancer research = Chung-kuo yen cheng yen chiu2025
Cancer statistics in China: Epidemiology, risk factors, and prevention.
Article in Chinese journal of cancer research = Chung-kuo yen cheng yen chiu, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Multi-cell death gene signature predicts lung adenocarcinoma prognosis and reveals FURIN regulates ferroptosis via NRF2-xCT-GPX4 axis.Respiratory research · 2026Article
- Recent Advances in Tumor-Infiltrating Lymphocyte Therapy for Melanoma.Current treatment options in oncology · 2026Review
- Cancer burden and control in China: landscape, trends and challenges.Nature reviews. Clinical oncology · 2026Review
- Lactobacillus plantarum-derived indole-3-lactic acid inhibits prostate cancer progression through ASF1B/ENO1 axis and remodels the tumor microenvironment to enhance anti-PD-1 therapy.Molecular biomedicine · 2026Article
- Quantitative CT analysis in lung cancer research: a bibliometric analysis based on Web of Science [2005-2025].Journal of thoracic disease · 2026Article
- Global research trends and hotspots in robotic-assisted prostate biopsy: a bibliometric analysis from 2008 to 2026.Journal of robotic surgery · 2026Article
- Perceived stigma among lung cancer patients: a cross-sectional study with latent profile analysis.BMC cancer · 2026Article
- Artificial intelligence empowered biomaterials for cancer therapy: From rational design to clinical translation.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2026Article
- Development of an interpretable machine learning model for lymphovascular space invasion prediction in patients with endometrioid endometrial carcinoma: A prospective study.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2026Article
- Circulating tumor cells with chromosome 8 aneuploidy are a diagnostic and prognostic monitoring biomarker for ovarian cancer.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2026Article
- Frontiers in bacterial outer membrane vesicles: From basic characteristics to cancer therapy.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2026Article
- Expert consensus on multidisciplinary management of laparoscopic-endoscopic cooperative surgery combined with sentinel lymph node navigation surgery for early gastric cancer (2026 edition).Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2026Article
- Chemotherapy-free regimen: Real-world efficacy and safety of anlotinib plus PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2026Article
- From HPV genotypes to cervical lesion burden: public health-relevant heterogeneity across 1.29 million screening records in Guangdong, China.Frontiers in public health · 2026Article
- Crosstalk in the brain tumor microenvironment: mechanisms, therapeutic strategies, and clinical advances.Military Medical Research · 2026Review
- Programmed Cell Death in Urological Cancers: Orchestrating the Immune Microenvironment and Immunotherapy.Oncology research · 2026Review
- Severe renal and pancreatic toxicities associated with ipilimumab and nivolumab combination therapy in non-small cell lung cancer: a pharmacovigilance analysis of the FDA adverse event reporting system.Frontiers in immunology · 2026Article
- YKT6 promotes breast cancer progression and is associated with poor prognosis and immune infiltration.Frontiers in immunology · 2026Article
- The enzymatic mechanisms of lactylation and its role in gynecological diseases: a comprehensive review.Frontiers in immunology · 2026Review
- Low follow-up rate after positive prostate cancer screening in southern China: a community-based cross-sectional survey with a prospective component.Frontiers in public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer is a leading cause of death in China, and its epidemiological profile has shifted markedly in recent years. This review summarizes contemporary trends in cancer incidence and mortality, delineates the major modifiable risk factors, and highlights recent national efforts to ease the burden of cancer. In 2022, China recorded 4.8 million new cancer cases (crude rate: 341.7 per 100,000) and 2.5 million cancer deaths (182.3 per 100,000). Lung, colorectal, thyroid, liver, stomach, and female breast cancers accounted for 65% of all diagnoses, while lung, liver, stomach, colorectal, and esophageal cancers constituted 67.5% of cancer deaths. Notable shifts in sex-specific rankings underscored the rising mortality burden of prostate, female breast, and cervical cancers. China has made measurable progress in cancer control. Between 2000 and 2018, the age-standardized mortality rate for all cancers declined by approximately 1.3% annually, and the age-standardized 5-year relative survival improved from 30.9% in 2003-2005 to 43.7% in 2019-2021. According to Global Burden of Disease (GBD) 2023, nearly half of cancer deaths and disability-adjusted life years (DALYs) were attributable to modifiable risk factors such as tobacco, air pollution, high alcohol use, dietary risks, and unsafe sex. In response, the government has implemented a suite of prevention-oriented policies, including expansion of human papillomavirus (HPV) vaccination, strengthened tobacco control, sustained air pollution reduction, enhanced health education, and broadened cancer screening coverage. Collectively, these initiatives demonstrate a sustained national commitment to reducing the cancer burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.